Risk of Underlying Diseases and Effectiveness of Drugs on COVID-19 Inpatients Assessed Using Medical Claims in Japan: Retrospective Observational Study

References

• Umakanthan S, Sahu P, Ranade AV, et al. Origin, transmission, diagnosis and management of coronavirus disease 2019 (COVID-19). Postgrad Med J. 2020;96(1142):753–758. doi:10.1136/postgradmedj-2020-138234
   PubMed Web of Science ®Google Scholar
• Ioannidis JPA. Infection fatality rate of COVID-19 inferred from seroprevalence data. Bull World Health Organ. 2021;99(1):19–33F. doi:10.2471/BLT.20.265892
   PubMed Web of Science ®Google Scholar
• Saini KS, Tagliamento M, Lambertini M, et al. Mortality in patients with cancer and coronavirus disease 2019: a systematic review and pooled analysis of 52 studies. Eur J Cancer. 2020;139:43–50. doi:10.1016/j.ejca.2020.08.011
   PubMed Web of Science ®Google Scholar
• Zhou Y, Yang Q, Chi J, et al. Comorbidities and the risk of severe or fatal outcomes associated with coronavirus disease 2019: a systematic review and meta-analysis. Int J Infect Dis. 2020;99:47–56. doi:10.1016/j.ijid.2020.07.029
   PubMed Web of Science ®Google Scholar
• Venkatesulu BP, Chandrasekar VT, Girdhar P, et al. A systematic review and meta-analysis of cancer patients affected by a novel coronavirus. JNCI Cancer Spectr. 2021;5(2):pkaa102. doi:10.1093/jncics/pkaa102
   PubMed Web of Science ®Google Scholar
• Salunke AA, Nandy K, Pathak SK, et al. Impact of COVID-19 in cancer patients on severity of disease and fatal outcomes: a systematic review and meta-analysis. Diabetes Metab Syndr. 2020;14(5):1431–1437. doi:10.1016/j.dsx.2020.07.037
   PubMed Web of Science ®Google Scholar
• Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335–337. doi:10.1016/S1470-2045(20)30096-6
   PubMed Web of Science ®Google Scholar
• Javanmardi F, Keshavarzi A, Akbari A, Emami A, Pirbonyeh N, Serra R. Prevalence of underlying diseases in died cases of COVID-19: a systematic review and meta-analysis. PLoS One. 2020;15(10):e0241265. doi:10.1371/journal.pone.0241265
   PubMed Web of Science ®Google Scholar
• Del Sole F, Farcomeni A, Loffredo L, et al. Features of severe COVID-19: a systematic review and meta-analysis. Eur J Clin Invest. 2020;50(10):e13378. doi:10.1111/eci.13378
   PubMed Web of Science ®Google Scholar
• Li J, Huang DQ, Zou B, et al. Epidemiology of COVID-19: a systematic review and meta-analysis of clinical characteristics, risk factors, and outcomes. J Med Virol. 2021;93(3):1449–1458. doi:10.1002/jmv.26424
   PubMed Web of Science ®Google Scholar
• Zheng Z, Peng F, Xu B, et al. Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis. J Infect. 2020;81(2):e16–e25. doi:10.1016/j.jinf.2020.04.021
   PubMed Web of Science ®Google Scholar
• Fadini GP, Morieri ML, Longato E, Avogaro A. Prevalence and impact of diabetes among people infected with SARS-CoV-2. J Endocrinol Invest. 2020;43(6):867–869. doi:10.1007/s40618-020-01236-2
   PubMed Web of Science ®Google Scholar
• Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821):430–436. doi:10.1038/s41586-020-2521-4
   PubMed Web of Science ®Google Scholar
• Killerby ME, Link-Gelles R, Haight SC, et al. Characteristics associated with hospitalization among patients with COVID-19 – Metropolitan Atlanta, Georgia, March-April 2020. MMWR Morb Mortal Wkly Rep. 2020;69(25):790–794. doi:10.15585/mmwr.mm6925e1
   PubMed Web of Science ®Google Scholar
• Wu T, Zuo Z, Kang S, et al. Multi-organ dysfunction in patients with COVID-19: a systematic review and meta-analysis. Aging Dis. 2020;11(4):874–894. doi:10.14336/AD.2020.0520
   PubMed Web of Science ®Google Scholar
• Zhang J, Wu J, Sun X, et al. Association of hypertension with the severity and fatality of SARS-CoV-2 infection: a meta-analysis. Epidemiol Infect. 2020;148:e106. doi:10.1017/S095026882000117X
   PubMed Web of Science ®Google Scholar
• Pranata R, Lim MA, Huang I, Raharjo SB, Lukito AA. Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: a systematic review, meta-analysis and meta-regression. J Renin Angiotensin Aldosterone Syst. 2020;21(2):1470320320926899. doi:10.1177/1470320320926899
   Web of Science ®Google Scholar
• The Cabinet Secretariat. Vaccination against SARS-CoV-2. Available from: https://www.kantei.go.jp/jp/headline/kansensho/vaccine.html. Accessed January 11, 2023.
   Google Scholar
• Umakanthan S, Lawrence S. Predictors of COVID-19 vaccine hesitancy in Germany: a cross-sectional, population-based study. Postgrad Med J. 2022;98(1164):756–764. doi:10.1136/postgradmedj-2021-141365
   PubMed Web of Science ®Google Scholar
• Mozaffari E, Chandak A, Zhang Z, et al. Remdesivir treatment in hospitalized patients with Coronavirus Disease 2019 (COVID-19): a comparative analysis of in-hospital all-cause mortality in a large multicenter observational cohort. Clin Infect Dis. 2022;75(1):e450–e458. doi:10.1093/cid/ciab875
   PubMed Web of Science ®Google Scholar
• Weinreich DM, Sivapalasingam S, Norton T, et al. REGEN-COV antibody combination and outcomes in outpatients with Covid-19. N Engl J Med. 2021;385(23):e81. doi:10.1056/NEJMoa2108163
   PubMed Web of Science ®Google Scholar
• Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab. N Engl J Med. 2021;385(21):1941–1950. doi:10.1056/NEJMoa2107934
   PubMed Web of Science ®Google Scholar
• Horby P, Lim WS, Emberson JR, et al; for RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384(8):693–704.
   PubMed Web of Science ®Google Scholar
• Marconi VC, Ramanan AV, de Bono S, et al; for COV-BARRIER Study Group. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled Phase 3 trial. Lancet Respir Med. 2021;9(12):1407–1418. doi:10.1016/S2213-2600(21)00331-3
   PubMed Web of Science ®Google Scholar
• Salama C, Han J, Yau L, et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. N Engl J Med. 2021;384(1):20–30. doi:10.1056/NEJMoa2030340
   PubMed Web of Science ®Google Scholar
• Gordon AC, Mouncey PR; REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N Engl J Med. 2021;384(16):1491–1502.
   PubMed Web of Science ®Google Scholar
• Umakanthan S, Senthil S, John S, et al. The effect of statins on clinical outcome among hospitalized patients with COVID-19: a multi-centric cohort study. Front Pharmacol. 2022;13:742273. doi:10.3389/fphar.2022.742273
   PubMed Web of Science ®Google Scholar
• Bergqvist R, Ahlqvist VH, Lundberg M, et al. HMG-CoA reductase inhibitors and COVID-19 mortality in Stockholm, Sweden: a registry-based cohort study. PLoS Med. 2021;18(10):e1003820. doi:10.1371/journal.pmed.1003820
   PubMed Web of Science ®Google Scholar
• Wong CKH, Au ICH, Lau KTK, Lau EHY, Cowling BJ, Leung GM. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study. Lancet. 2022;400(10359):1213–1222. doi:10.1016/S0140-6736(22)01586-0
   PubMed Web of Science ®Google Scholar
• Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. N Engl J Med. 2022;386(6):509–520. doi:10.1056/NEJMoa2116044
   PubMed Web of Science ®Google Scholar
• Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med. 2022;386(15):1397–1408. doi:10.1056/NEJMoa2118542
   PubMed Web of Science ®Google Scholar
• Ministry of Health, Labour and Welfare. 医療施設調査 [Survey of medical institutions]. Japanese. Available from: https://www.mhlw.go.jp/toukei/saikin/hw/iryosd/20a/. Accessed June 20, 2022.
   Google Scholar
• Kanazawa N, Tani T, Imai S, Horiguchi H, Fushimi K, Inoue N. Existing data sources for clinical epidemiology: database of the National Hospital Organization in Japan. Clin Epidemiol. 2022;14:689–698. doi:10.2147/CLEP.S359072
   PubMed Web of Science ®Google Scholar
• Ivashchenko AA, Dmitriev KA, Vostokova NV, et al. AVIFAVIR for treatment of patients with moderate Coronavirus Disease 2019 (COVID-19): interim results of a Phase II/III multicenter randomized clinical trial. Clin Infect Dis. 2021;73(3):531–534. doi:10.1093/cid/ciaa1176
   PubMed Web of Science ®Google Scholar
• Fujii S, Ibe Y, Ishigo T, et al. Early favipiravir treatment was associated with early defervescence in non-severe COVID-19 patients. J Infect Chemother. 2021;27(7):1051–1057. doi:10.1016/j.jiac.2021.04.013
   PubMed Web of Science ®Google Scholar
• Capochiani E, Frediani B, Iervasi G, et al. Ruxolitinib rapidly reduces acute respiratory distress syndrome in COVID-19 disease. Analysis of data collection from RESPIRE protocol. Front Med. 2020;7:466. doi:10.3389/fmed.2020.00466
   Web of Science ®Google Scholar
• Cao B, Wang Y, Wen D, et al. A trial of Lopinavir-Ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382(19):1787–1799. doi:10.1056/NEJMoa2001282
   PubMed Web of Science ®Google Scholar
• Quinn TM, Gaughan EE, Bruce A, et al. Randomised controlled trial of intravenous nafamostat mesylate in COVID pneumonitis: phase 1b/2a experimental study to investigate safety, pharmacokinetics and pharmacodynamics. EBioMedicine. 2022;76:103856. doi:10.1016/j.ebiom.2022.103856
   PubMed Web of Science ®Google Scholar
• Gunst JD, Staerke NB, Pahus MH, et al. Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial. EClinicalMedicine. 2021;35:100849. doi:10.1016/j.eclinm.2021.100849
   PubMedGoogle Scholar
• Duvignaud A, Lhomme E, Onaisi R, et al. Inhaled ciclesonide for outpatient treatment of COVID-19 in adults at risk of adverse outcomes: a randomised controlled trial (COVERAGE). Clin Microbiol Infect. 2022;28(7):1010–1016. doi:10.1016/j.cmi.2022.02.031
   PubMed Web of Science ®Google Scholar
• Terada-Hirashima J, Suzuki M, Tsujimoto Y, et al. Impact of inhaled ciclesonide on asymptomatic or mild COVID-19: a randomized trial. Drug Discov Ther. 2022;16(5):225–232. doi:10.5582/ddt.2022.01068
   PubMed Web of Science ®Google Scholar
• López-Medina E, López P, Hurtado IC, et al. Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19: a randomized clinical trial. JAMA. 2021;325(14):1426–1435. doi:10.1001/jama.2021.3071
   PubMed Web of Science ®Google Scholar
• Abadie A, Imbens GW. Large sample properties of matching estimators for average treatment effects. Econometrica. 2006;74:235–267. doi:10.1111/j.1468-0262.2006.00655.x
   Web of Science ®Google Scholar
• Abadie A, Imbens GW. On the failure of the bootstrap for matching estimators. Econometrica. 2008;76:1537–1557.
   Web of Science ®Google Scholar
• Abadie A, Imbens GW. Bias-corrected matching estimators for average treatment effects. J Bus Econ Stat. 2011;29:1–11. doi:10.1198/jbes.2009.07333
   Web of Science ®Google Scholar
• Cohen JB, Hanff TC, William P, et al. Continuation versus discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial. Lancet Respir Med. 2021;9(3):275–284. doi:10.1016/S2213-2600(20)30558-0
   PubMed Web of Science ®Google Scholar
• Reynolds HR, Adhikari S, Pulgarin C, et al. Renin–angiotensin–aldosterone system inhibitors and risk of Covid-19. N Engl J Med. 2020;382(25):2441–2448. doi:10.1056/NEJMoa2008975
   PubMed Web of Science ®Google Scholar
• Alhaddad MJ, Almulaify MS, Alshabib AA, et al. Relation between renin–angiotensin–aldosterone system inhibitors and COVID-19 severity. Cureus. 2022;14(3):e22903. doi:10.7759/cureus.22903
   PubMed Web of Science ®Google Scholar
• Kurdi A, Mueller T, Weir N. An umbrella review and meta-analysis of renin–angiotensin system drugs use and COVID-19 outcomes. Eur J Clin Invest. 2023;53(2):e13888. doi:10.1111/eci.13888
   PubMed Web of Science ®Google Scholar
• Guo X, Zhu Y, Hong Y. Decreased mortality of COVID-19 with renin–angiotensin–aldosterone system inhibitors therapy in patients with hypertension: a meta-analysis. Hypertension. 2020;76(2):e13–e14. doi:10.1161/HYPERTENSIONAHA.120.15572
   PubMed Web of Science ®Google Scholar
• Peng M, He J, Xue Y, Yang X, Liu S, Gong Z. Role of hypertension on the severity of COVID-19: a review. J Cardiovasc Pharmacol. 2021;78(5):e648–e655. doi:10.1097/FJC.0000000000001116
   PubMed Web of Science ®Google Scholar
• Chen R, Yang J, Gao X, et al. Influence of blood pressure control and application of renin–angiotensin–aldosterone system inhibitors on the outcomes in COVID-19 patients with hypertension. J Clin Hypertens. 2020;22(11):1974–1983. doi:10.1111/jch.14038
   Web of Science ®Google Scholar
• Sharafeldin N, Bates B, Song Q, et al. Outcomes of COVID-19 in patients with cancer: report from the national COVID cohort collaborative (N3C). J Clin Oncol. 2021;39(20):2232–2246. doi:10.1200/JCO.21.01074
   PubMed Web of Science ®Google Scholar
• Thompson MG, Burgess JL, Naleway AL, et al. Prevention and attenuation of Covid-19 with the BNT162b2 and mRNA-1273 vaccines. N Engl J Med. 2021;385(4):320–329. doi:10.1056/NEJMoa2107058
   PubMed Web of Science ®Google Scholar
• Larson HJ, Jarrett C, Eckersberger E, Smith DM, Paterson P. Understanding vaccine hesitancy around vaccines and vaccination from a global perspective: a systematic review of published literature, 2007–2012. Vaccine. 2014;32(19):2150–2159. doi:10.1016/j.vaccine.2014.01.081
   PubMed Web of Science ®Google Scholar
• Umakanthan S, Bukelo MM, Bukelo MJ, Patil S, Subramaniam N, Sharma R. Social environmental predictors of COVID-19 vaccine hesitancy in India: a population-based survey. Vaccines. 2022;10(10):1749. doi:10.3390/vaccines10101749
   Web of Science ®Google Scholar
• Kurita J, Sugawara T, Ohkusa Y. Pathogenicity of the omicron variant strain comparison with delta variant strain and seasonal influenza in Japan. Available from: https://jxiv.jst.go.jp/index.php/jxiv/preprint/view/59. Accessed August 10, 2022.
   Google Scholar
• Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol. 2008;167(4):492–499. doi:10.1093/aje/kwm324
   PubMed Web of Science ®Google Scholar
• Williamson T, Ravani P. Marginal structural models in clinical research: when and how to use them? Nephrol Dial Transplant. 2017;32(suppl_2):ii84–ii90. doi:10.1093/ndt/gfw341
   PubMedGoogle Scholar